CMND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Clearmind Medicine Inc (CMND) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock shows no significant bullish technical signals, lacks positive financial performance, and has no strong trading trends or proprietary trading signals. While there is potential in its MEAI drug development, it is still in early stages and speculative. A hold is recommended until more concrete progress or financial stability is demonstrated.
The MACD is positive and expanding, which is a mildly bullish indicator. However, the RSI is neutral at 32.812, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 1.378, with key support at 1.068 and resistance at 1.687. Overall, the technical indicators do not suggest a strong buy opportunity.
Clearmind's MEAI drug shows potential for significant weight reduction in obesity treatment and is advancing in FDA-approved trials for alcohol use disorder. The obesity market is projected to exceed $100 billion, presenting a large potential market for the company.
The company has no revenue and reported a significant net income loss of -687,842 in Q4 2025, with a YoY decline of -22.26%. EPS also dropped significantly by -41.98% YoY. The bearish moving averages and lack of significant trading trends further weigh against the stock.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income loss of -687,842, down -22.26% YoY. EPS dropped to -5.03, a decline of -41.98% YoY. Gross margin remained at 0%. The financial performance is weak and not supportive of a buy recommendation.
No analyst rating or price target changes are provided. However, Goldman Sachs highlights the potential of the obesity market, which could benefit Clearmind if its MEAI drug succeeds.
